Cynomolgus studies with lead TRACTrs have demonstrated safety proof-of-concept to support IND-enabling development activities. Janux-led TRACTr development candidate selection is ongoing with multiple programs entering IND-enabling studies in 2021 to provide a broad portfolio of tumor-specific immune-activating therapeutics.

Lead DiscoveryLead OptimizationIND EnablingPhase 1
T1-TRACTr

T2-TRACTr

T3-TRACTr

Discovery Programs

DrugStage
T1-TRACTr
IND Enabling
T2-TRACTr
Lead Optimization
T3-TRACTr
Lead Optimization
Discovery Programs
Lead Discovery